Jazz Pharmaceuticals vs Organon &
Organon & is the larger business, with $6.22bn of revenue in fiscal 2025 against $4.27bn for Jazz Pharmaceuticals (1.5 times as much). Jazz Pharmaceuticals grew faster (4.9% against -2.9%). Organon & kept more of each dollar of sales as profit: a net margin of 3.0% against -8.3%. Jazz Pharmaceuticals carries less debt relative to equity (125.3% against 1149.5%).
| Latest fiscal year | Jazz PharmaceuticalsJAZZ, 2025 | Organon &OGN, 2025 |
|---|---|---|
| Revenue | $4.27bn | $6.22bn |
| Revenue growth | 4.9% | -2.9% |
| Net income | −$356m | $187m |
| Operating margin | -10.1% | — |
| Net margin | -8.3% | 3.0% |
| Return on equity | -8.5% | 30.6% |
| Free cash flow | $1.30bn | $538m |
| Cash | $1.39bn | $574m |
| Total debt | $5.41bn | $8.64bn |
| Debt to equity | 125.3% | 1149.5% |
| Dividend per share | — | $0.34 |
| Dividend yield | — | 0.6% |
| Share buybacks | $125m | — |
| Employees | 700 | 10,000 |
| Market value | $15.09bn | $3.64bn |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 66 (Moderate) | 56 (Moderate) |
| Insider trades, 12 months | 0 buys, 59 sales | 2 buys, 2 sales |